| Spotlight |
 |
|
Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.
|
| Latest news |
|
|
At CDMI Europe 2025, experts agreed that AI is the key technology to improve efficiencies in clinical trial data management.
|
|
|
Tecvayli + Darzalex delivers superior efficacy in early relapsed MM, positioning J&J to dominate the R/R market.
|
|
|
Tazarotene demonstrated promising efficacy and safety in a mid-stage study, meeting primary and secondary endpoints.
|
|
|
The study will be carried out at up to 60 ALS treatment centres across Canada, the EU, the US, Israel and the UK.
|
|
|
The partnership aims to streamline the transition between development phases and CRO partners.
|
|
|
|
